Summary & Overview
HCPCS G0138: Intravenous Infusion of Cipaglucosidase Alfa-atga
HCPCS Level II code G0138 represents the intravenous infusion of cipaglucosidase alfa-atga and includes provider/supplier acquisition plus clinical supervision of oral miglustat administration in preparation for the infusion. The code captures a bundled service that spans medication procurement, supervised oral premedication, and the infusion encounter, making it relevant for specialty infusion programs and payer coverage determinations for rare-disease enzyme-replacement therapies. Nationally, accurate use of G0138 affects reimbursement, care coordination, and claims processing for high-cost biologic infusions.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code denotes, payer coverage scope, and the clinical context for use. The publication outlines typical benchmarks and policy-relevant considerations for coding and claims adjudication, notes common modifiers used in practice (input provided), and situates the service in expected sites of care such as ambulatory infusion centers and hospital outpatient infusion clinics. The analysis also highlights where input data were not available and identifies areas—such as associated taxonomies, specific ICD-10 diagnoses, related HCPCS codes, and service-line details—where further payer- or provider-supplied information is required for complete billing workflows.
Billing Code Overview
HCPCS Level II code G0138 describes the intravenous infusion of cipaglucosidase alfa-atga, and explicitly includes provider or supplier acquisition and clinical supervision of oral administration of miglustat in preparation for receipt of the infused product. This service represents a combined therapy preparation and infusion encounter where a clinician oversees both the medication procurement and the oral pre-treatment steps necessary for administration.
-
Service type: Infusion therapy with clinical supervision of oral pre-medication
-
Typical site of service: Ambulatory infusion center, hospital outpatient infusion clinic, or specialty infusion provider setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with confirmed late-onset Pompe disease (glycogen storage disease type II) presents for outpatient enzyme replacement therapy. The patient is scheduled for an intravenous infusion of G0138 (cipaglucosidase alfa-atga). Prior to infusion, the patient receives oral miglustat under clinical supervision per recommended co‑administration protocol to stabilize uptake. The workflow includes pre-infusion nursing assessment (vitals, weight, allergy review), verification of medication orders and provider acquisition documentation, oral administration and observation for miglustat tolerance, placement of IV access, infusion initiation and rate titration, continuous monitoring for infusion‑related reactions, and post‑infusion observation and discharge instructions. Documentation must include indication, consent, drug lot numbers, infusion start/stop times, total dose and units infused, any infusion reactions and treatments, and supervision notes for the oral miglustat administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | When no other modifier applies and standard reporting is appropriate |
22 |